SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Trump Says Anthropic No Longer Seen as National Security Threat 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
LEXINGTON, Mass., Jan. 26, 2016 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2015 fourth quarter and year-end financial results after the market closes on Tuesday, February 16, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, February 16, 2016, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-4018 (U.S.) or 1-201-689-8471 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call in the Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established. For more information, please visit www.t2biosystems.com.
Media Contact: Susan Heins, Pure Communications [email protected] 864-286-9597 Investor Contact: Matt Clawson, Pure Communications [email protected] 949-370-8500
